axicabtagene ciloleucel Yescarta
Selected indexed studies
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (N Engl J Med, 2022) [PMID:34891224]
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. (Lancet Oncol, 2019) [PMID:30518502]
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. (Lancet Oncol, 2022) [PMID:34895487]
_Worker-drafted node — pending editorial review._
Connections
axicabtagene ciloleucel Yescarta is a side effect of
Sources
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. (2019) pubmed
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. (2022) pubmed
- Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. (2023) pubmed
- Axicabtagene Ciloleucel. (2006) pubmed
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. (2022) pubmed
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. (2023) pubmed
- EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma. (2020) pubmed
- PMID:38564541 (2024) pubmed
- PMID:38320060 (2023) pubmed
- PMID:37797108 (2023) pubmed